CATTANEO, DANIELE
CATTANEO, DANIELE
Dipartimento di Oncologia ed Emato-Oncologia
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
2024 O. Mulas, E. Abruzzese, L. Luciano, A. Iurlo, I. Attolico, F. Castagnetti, S. Galimberti, M. Bonifacio, M. Annunziata, A. Gozzini, E.M. Orlandi, F. Stagno, G. Binotto, P. Pregno, C. Fozza, M. Loi, M.M. Trawinska, F. De Gregorio, D. Cattaneo, F. Albano, M. Iezza, C. Baratè, L. Scaffidi, C. Elena, V. Giai, E. Scalzulli, M. Breccia, G. La Nasa, G. Caocci
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2024 T. Barbui, A. Carobbio, V. De Stefano, A. Alvarez-Larran, A. Ghirardi, G. Carioli, F. Fenili, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, L. Calabresi, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Ramundo, F. Lunghi, L. Scaffidi, C. Bucelli, D. Cattaneo, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi, A.M. Vannucchi
Neutrophilic and eosinophilic dermatoses associated with hematological malignancy
2024 C.A. Maronese, F. Derlino, C. Moltrasio, D. Cattaneo, A. Iurlo, A.V. Marzano
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective
2024 C. Pescia, G. Lopez, D. Cattaneo, C. Bucelli, U. Gianelli, A. Iurlo
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis
2024 V. Abbonante, A.I. Karkempetzaki, C. Leon, A. Krishnan, N. Huang, C.A. Di Buduo, D. Cattaneo, C.M. Ward, S. Matsuura, I. Guinard, J. Weber, A. De Acutis, G. Vozzi, A. Iurlo, K. Ravid, A. Balduini
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
2023 A. Iurlo, D. Cattaneo, D. Consonni, F. Castagnetti, M.C. Miggiano, G. Binotto, M. Bonifacio, G. Rege-Cambrin, M. Tiribelli, F. Lunghi, A. Gozzini, P. Pregno, E. Abruzzese, I. Capodanno, C. Bucelli, M. Pizzuti, S. Artuso, M. Iezza, E. Scalzulli, G. La Barba, A. Maggi, S. Russo, C. Elena, A.R. Scortechini, A. Tafuri, R. Latagliata, G. Caocci, M. Bocchia, S. Galimberti, L. Luciano, C. Fava, R. Foà, G. Saglio, G. Rosti, M. Breccia
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs
2023 A. Iurlo, C. Bucelli, D. Cattaneo
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort
2023 D. Cattaneo, C. Bucelli, A. Marchetti, M. Lionetti, E. Fermo, V. Bellani, C. De Magistris, A. Maeda, A. Marella, M. Primignani, D. Consonni, U. Gianelli, A. Neri, L. Baldini, N. Bolli, A. Iurlo
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
2023 A. Iurlo, D. Cattaneo
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies
2023 A. Iurlo, D. Cattaneo, C. Bucelli, P. Spallarossa, F. Passamonti
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
2023 F. Palandri, G. Alberto Maria PALUMBO, M. Bonifacio, E. Maria Elli, M. Tiribelli, G. Auteri, M.M. Trawinska, N. Polverelli, G. Benevolo, A. Tieghi, F. Cavalca, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, M. Venturi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, E. Abruzzese, F. Branzanti, N. Vianelli, M. Cavo, F. Heidel, A. Iurlo, M. Breccia
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases
2023 V. Bellani, G.A. Croci, C. Bucelli, C.A. Maronese, S. Alberti, A. Iurlo, D. Cattaneo
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023 F. Palandri, E.M. Elli, G. Auteri, M. Bonifacio, G. Benevolo, F.H. Heidel, S. Paglia, M.M. Trawinska, C. Bosi, E. Rossi, M. Tiribelli, A. Tieghi, A. Iurlo, N. Polverelli, G. Caocci, G. Binotto, F. Cavazzini, E. Beggiato, D. Cilloni, C. Tatarelli, F. Mendicino, M. Miglino, M. Bocchia, M. Crugnola, C. Mazzoni, A.D. Romagnoli, G. Rindone, S. Ceglie, A. D'Addio, E. Santoni, D. Cattaneo, D. Bartoletti, R.M. Lemoli, M. Krampera, A. Cuneo, G.C. Semenzato, R. Latagliata, E. Abruzzese, N. Vianelli, M. Cavo, A. Andriani, V. De Stefano, G.A. Palumbo, M. Breccia
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
2023 F. Palandri, M. Breccia, C. Mazzoni, G. Auteri, E.M. Elli, M.M. Trawinska, N. Polverelli, M. Tiribelli, G. Benevolo, A. Iurlo, A. Tieghi, F.H. Heidel, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, M. Biondo, M. Venturi, L. Scaffidi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, E. Abruzzese, D. Bartoletti, S. Paglia, N. Vianelli, M. Cavo, M. Bonifacio, G.A. Palumbo
Second versus first wave of COVID-19 in patients with MPN
2022 T. Barbui, A. Iurlo, A. Masciulli, A. Carobbio, A. Ghirardi, G. Carioli, M.A. Sobas, E.M. Elli, E. Rumi, V. De Stefano, F. Lunghi, M. Marchetti, R. Daffini, M. Gasior Kabat, B. Cuevas, M.L. Fox, M.M. Andrade-Campos, F. Palandri, P. Guglielmelli, G. Benevolo, C. Harrison, M.A. Foncillas, M. Bonifacio, A. Alvarez-Larran, J.-. Kiladjian, E. Bolanos Calderon, A. Patriarca, K. Quiroz Cervantes, M. Griessammer, V. Garcia-Gutierrez, A. Marin Sanchez, E. Magro Mazo, M. Ruggeri, J.C. Hernandez-Boluda, S. Osorio, G. Carreno-Tarragona, M. Sagues Serrano, R. Kusec, B. Navas Elorza, A. Angona, B. Xicoy Cirici, E. Lopez Abadia, S. Koschmieder, D. Cattaneo, C. Bucelli, E. Cichocka, A. Masternak Kulikowska de Nalecz, F. Cavalca, O. Borsani, S. Betti, L. Benajiba, M. Bellini, N. Curto-Garcia, A. Rambaldi, A.M. Vannucchi
Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease
2022 S. Ferrucci, L. Angileri, S. Tavecchio, S. Fumagalli, A. Iurlo, D. Cattaneo, A.V. Marzano, C.A. Maronese
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
2022 T. Barbui, A. Carobbio, A. Ghirardi, A. Iurlo, M.A. Sobas, E.M. Elli, E. Rumi, V. De Stefano, F. Lunghi, M. Marchetti, R. Daffini, M. Gasior Kabat, B. Cuevas, M.L. Fox, M.M. Andrade-Campos, F. Palandri, P. Guglielmelli, G. Benevolo, C. Harrison, M. Foncillas, M. Bonifacio, A. Alvarez-Larran, J. Kiladjian, E. Bolaños Calderón, A. Patriarca, K. Quiroz Cervantes, M. Griesshammer, V. Garcia-Gutierrez, A. Marin Sanchez, E. Magro Mazo, G. Carli, J.C. Hernandez-Boluda, S. Osorio, G. Carreno-Tarragona, M. Sagues Serrano, R. Kusec, B. Navas Elorza, A. Angona, B. Xicoy Cirici, E. Lopez Abadia, S. Koschmieder, D. Cattaneo, C. Bucelli, E. Cichocka, A.K. de Nałęcz, F. Cavalca, O. Borsani, S. Betti, M. Bellini, N. Curto-Garcia, A. Rambaldi, A.M. Vannucchi
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
2022 D. Cattaneo, C. Vener, E.M. Elli, C. Bucelli, N. Galli, F. Cavalca, G. Auteri, D. Vincelli, B. Martino, U. Gianelli, F. Palandri, A. Iurlo